Ten percent of CRC patients are diagnosed with mutations in the BRAF oncogene of the MAPK pathway, and the most common missense mutation occurs at the 600th amino acid with a valine to glutamic acid (V600E) change, predicting distant metastasis and poor prognosis (2). Here, BRAF is linked to colorectal carcinoma.